NVIDIA has released a major new update for its RTX Remix modding platform, bringing several substantial improvements to rendering quality, performance, and modding capabilities. Available through ...

Recursive, an AI startup founded last year, is starting to live up to its name. The company, which is trying to build AI that can improve itself, released its first model, Flint, on Wednesday. Flint ...

Flint launched on October 21, 2026. It is a 40-billion-parameter model built specifically for coding work. On a MacBook Pro with an M4 Pro chip, Flint generates over 125 tokens per second. On RTX ...

arXiv:2610.08621v1 Announce Type: new Abstract: Recent game design agents have made substantial progress in generating playable games. However, program correctness does not ensure an enjoyable ...

Recent game design agents have made substantial progress in generating playable games. However, program correctness does not ensure an enjoyable experience for players. We present Recursive Game ...

Showing the original English abstract. Click "Iniciar Chat" and AI can explain this paper in your language. Recent game design agents have made substantial progress in generating playable games.

A 78-second narrated walkthrough — the loop, worked through one game from its first playable version to the build development delivers, and what it does across the benchmark. Unmute to play with sound ...

“Recursive self-improvement” is the idea that artificial intelligence could learn to build and train itself, creating exponential new progress — and risk. Jeff Clune, a computer scientist and ...

All the Latest Game Footage and Images from Recursion: Alignment Run an AI lab. Ship models. Survive what they learn to fake. A satirical management sim about GPUs, researchers, investors, and the ...

Until Dawn developer Supermassive Games has announced layoffs impacting up to 75 staff — the studio's third round of job losses in three years. This latest round of cuts was confirmed publicly today ...

Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and ...